Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats

Prostate

Volumn 38, Issue 1, 1999, Pages 17-27

  Shakutou, Shuuji ^a,d   Bandoh, Kohsuke ^a   Yoshinaka, Yasunobu ^b   Kobayashi, Hideyuki ^b   Yamanaka, Hidetoshi ^c  

^a SANOFI   (France)

^b KOWA COMPANY LTD   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d NONE   (Japan)

Author keywords

Intestinal absorption; Polyene antibiotics; Prostatic hyperplasia; Sex hormones

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; MEPARTRICIN; POLYENE ANTIBIOTIC AGENT; SEX HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; EPITHELIUM CELL; ESTROGEN BINDING; INTESTINE ABSORPTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; RAT; SEMINAL VESICLE; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FECES; LUTEINIZING HORMONE; MALE; MEPARTRICIN; PROSTATE; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; SPECTROPHOTOMETRY; TESTOSTERONE;

EID: 0032949588     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990101)38:1<17::AID-PROS2>3.0.CO;2-T     Document Type: Article

References (34)

1. Walsh PC. Benign prostatic hyperplasia. In: Walsh PC, Retic AB, Stamey TA, Vaughan ED Jr, editors. Campbell's Urology, 6th ed. Philadelphia: W.B. Saunders; 1992. p 1009-1027.
2. Berry SJ. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479.
3. Yamanaka H, Imai, K, Suzuki T, Mashimo T. Fundamental causes, diagnosis and treatment of benign prostatic hyperplasia. Med Drug J 1990;26:1207-1212 [in Japanese only].
4. Ooe H. The aging of society and benign prostatic hyperplasia. Med Drug J 1990;26:989-994 [in Japanese only].
5. Belham JE, Neal GE. Testosterone action in the rat ventral prostate. Biochem J 1971;125:81-91.
6. Lee CH, Jesik CH. Effects of castration, estrogen, and androgen administration. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983. p 229-234.
7. Neubauer BL. Endocrine and cellular factors in the development of human benign prostatic hypertrophy. In: Hinman F Jr, editor. Benign Prostatic Hypertrophy. New York: Springer-Verlag; 1983. p 179-192.
8. Vermeulen A. Testicular hormonal secretion and aging in mammals. In: Grayhack JT, Wilson JD, Scherbenske MJ, editors. Benign Prostatic Hyperplasia. Washington, DC: DHEW Publication (NIH); 1975. p 177-181.
9. Griffiths K, Eaton CL, Harper ME, Peeling B, Davies P. Steroid hormones and the pathogenesis of benign prostatic hyperplasia. Eur Urol [Suppl] 1991;20:68-77.
10. Pike KM, Doerr P. Age related changes in free plasma testosterone, dihyrotestosterone and estradiol. Acta Endocrinol (Copenh) 1970;80:171-178.
11. Kozak I, Bartsch W, Krieg M, Voigt KD. Nuclei of stroma: Site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate 1982;3:433-438.
12. Skoldefors H, Carlstrom K, Furuhjelm M. Urinary hormone excretion in benign prostatic hyperplasia. J Steroid Biochem 1976; 7:477-480.
13. Karr JP, Wajsman Z, Madajewicz S, Kirdani RY, Murphy GP, Sandberg AA. Steroid hormone receptors in the prostate. J Urol 1979;122:170-175.
14. Krieg M, Bartsch W, Thomsen M, Voigt KD. Androgens and estrogens: Their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem 1983;19:155-161.
15. Collins AT, Zhiming B, Gilmore K, Neal DE. Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: Oestrogen regulation of the androgen receptor. J Endocrinol 1994;143:269-277.
16. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976;57:1093-1097.
17. Trachtenberg J, Hicks LL, Walsh PC. Androgen-and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest 1980;65:1051-1059.
18. Del Vecchio S, Ulissi A, Delle Monache M, Tavanti A, Rapocci M, Ruozi P, De Bernardi M, Ricci GL. Faecal elimination of steroids in rats after oral administration of mepartricin. J Int Med Res 1990;18:468-472.
19. Lotti T, Mirone V, Prezioso D, De Bernardi M, Rapocci MP, Ruozi P. Observations on some hormone fractions in patients with benign prostatic hyperplasia treated with mepartricin. Curr Ther Res 1988;44:402-409.
20. De Bernardi M, Rollero M, Goi A. Rilievi morfologici della ghiandola prostatica dopo trattamento con mepartricina studio istopatologico sul cane [Morphologic controls of prostatic gland after treatment with mepartricin histopathological study in dog]. Acta Toxicol Ther 1986;7:13-19.
21. Mobbs BG, Johnson IE, Liu Y. Quantitation of cytosolic and nuclear estrogen and progesterone receptor in benign, untreated, and treated malignant human prostatic tissue by radioligand binding and enzyme-immunoassays. Prostate 1990;16: 235-244.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RG. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193: 265-275.
23. Schroeder FH, MacKensen SJ. Human prostatic adenoma and carcinoma in cell culture: Effects of androgen-free culture medium. Invest Urol 1974;12:176-181.
24. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free primary cell culture. Cancer Res 1994;44:1998-2010.
25. Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993;77:375-381.
26. Mawhinney MG, Neubauer BL. Actions of estrogen in the male. Invest Urol 1979;16:409-420.
27. Adlercreutz H, Martin F. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem 1980;13:231-244.
28. Cheron M, Cybulska B, Mazerski J, Grzybowska J, Czerwinski A, Borowski E. Quantitative structure-activity relationships in amphotericin B derivatives. Biochem Pharmacol 1988;37:827-836.
29. Lampen JO, Arnow PM, Safferman RS. Mechanism of protection by sterol against polyene antibiotics. J Bacteriol 1960;80:200-206.
30. Ghelfi R, Corce A, Mangiagalli M. Pharmacokinetics of mepartricin. Note 1: Absorption and excretion of its insoluble form. Therap Antibiot Chemother 1978;28:3-6.
31. Swaneck GE, Alvarez JM, Sufrin G. Multiple species of estrogen binding sites in the nuclear fraction of the rat prostate. Biochem Biophys Res Commun 1982;106:1441-1447.
32. Ip MM, Milholland RJ, Rosen F. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma. Cancer Res 1980;40:2188-2193.
33. Moore RJ, Gazak JM, Wilson JD. Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17β-estradiol. J Clin Invest 1979;63:351-357.
34. Bouton MM, Pornin C, Grandadam JA. Estrogen regulation of rat prostate androgen receptor. J Steroid Biochem 1981;15:403-408.